Rosetta Genomics this week announced that it has signed a deal giving the Italian commercialization rights to its three microRNA-based diagnostics to AXA Diagnostics.
Under the deal, privately held AXA will market in Italy Rosetta's miRview Meso, which differentiates lung cancer from mesothelioma; miRview Mets, which is designed to determine the source of cancers of unknown primary origin; and miRview Squamous, which is designed to differentiate squamous from non-squamous non-small cell lung cancer.
Tissue samples will be sent from AXA to Rosetta’s Philadelphia-based laboratory for analysis. Specific terms of the arrangement were not disclosed.
The announcement of the deal comes less than a month after Rosetta announced that it has licensed the rights to the diagnostics in India, Saudi Arabia, Qatar, and the United Arab Emirates to India’s Super Religare Laboratories (see RNAi News, 8/20/2009).
That same month, Rosetta licensed the diagnostics’ Canadian market rights to Warnex Medical Laboratories (see RNAi News, 8/13/2009).
In April, Rosetta signed a deal giving Prometheus Laboratories the US rights to the three tests (see RNAi News, 4/16/2009). In January, it licensed the Israeli and Turkish rights to Teva Pharmaceuticals (see RNAi News, 1/8/2009).